Morgan Stanley lowered the firm’s price target on Inspire Medical (INSP) to $220 from $230 and keeps an Overweight rating on the shares. Though ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results